| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Iterum Therapeutics Plc (ITRM) has 2 insiders with recent SEC Form 4 filings, including 10 buys and 0 sells. ITRM is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 241.0K | $88.0K | - | |
| Other | 200.0K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 30, 2018 | Chin Mark | Director | Buy | 337,606 | $13.00 | $4,388,878.00 | +48.6% | |
| May 30, 2018 | Lathi Vijay K | 10% Owner | Buy | 662,677 | $13.00 | $8,614,801.00 | +83.5% | |
| May 30, 2018 | Hunt Ronald | Director, 10% Owner | Buy | 662,677 | $13.00 | $8,614,801.00 | +83.5% | |
| May 30, 2018 | Malik Shahzad | Director | Buy | 236,984 | $13.00 | $3,080,792.00 | +37.5% | |
| May 30, 2018 | Ahrens Brenton Karl88 | Director | Buy | 506,656 | $13.00 | $6,586,528.00 | +41.3% | |
| May 30, 2018 | Dunne Michael W. | Chief Scientific Officer | Buy | 2,000 | $13.00 | $26,000.00 | +1.4% | |
| May 30, 2018 | Fishman Corey N. | President &CEO | Buy | 3,000 | $13.00 | $39,000.00 | +1.3% |